Welcome to our dedicated page for Beyond Air SEC filings (Ticker: XAIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Beyond Air, Inc. filings document the regulatory record for a commercial-stage nitric oxide medical device and biopharmaceutical company. Proxy materials cover stockholder votes on charter amendments, reverse stock-split authority, director elections, auditor ratification, and equity incentive plan share reserves.
Form 8-K disclosures record material events such as executive officer transitions, separation agreements, Nasdaq continued-listing compliance notices, annual meeting results, material agreements, capital-structure matters, operating and financial results, and clinical or regulatory disclosures tied to the company's nitric oxide programs.
Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.
Beyond Air (NASDAQ: XAIR) reported several significant developments in this 8-K filing:
Key Events:
- Released financial results for fiscal quarter and year ended March 31, 2025 (detailed results not provided in filing)
- Appointed Robert Goodman to Board of Directors on June 16, 2025 - Qualified as independent director under Nasdaq standards - Notable experience with BioTelemetry, Philips Healthcare, Cardiocore, Thermo Fisher Scientific, and Pfizer
- Submitted PMA supplement application to FDA for LungFit PH II, their next-generation therapeutic nitric oxide generator
The company filed two press releases as exhibits (99.1 and 99.2) detailing the financial results and FDA submission respectively. The appointment of Goodman strengthens the board with extensive healthcare industry expertise, while the FDA submission represents a significant regulatory milestone for their therapeutic device development program.